← Leaderboards
Lawrence Paul Wennogle
Intra-Cellular Therapies, Inc.
$4,243,293
Attributed
$4,243,293
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $968K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$4,243,293 · 1
By mechanism
R44$4,243,293 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCalmodulin Dependent PhosphodiesteraseInhibitor/AntagonistNational Institute Of Mental Health (U.S.)Research ContractsBaseDoseHousingLeadMediatingPhosphoric Diester HydrolaseProgramsBehavioralSmall MoleculeAntidepressive AgentsCostChronicFundingBrainClinical TrialsMeasurementBehavioral ModelAnimal ModelBehavior
Grant awards (6)
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia$964,601
R44 · FY2010 · MH · contact PI
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia$964,465
R44 · FY2009 · MH · contact PI
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia$968,007
R44 · FY2008 · MH · contact PI
Novel PDE Inhibitors for Depression$463,329
R44 · FY2007 · MH · contact PI
Novel PDE Inhibitors for Depression$419,139
R44 · FY2006 · MH · contact PI
Novel PDE Inhibitors for Depression$463,752
R44 · FY2005 · MH